Biocon Chairperson Kiran Mazumdar-Shaw has said that US President Donald Trump would focus on introducing new pricing models that will make expensive innovative drugs more affordable. “If controlling healthcare costs is a priority...Indian pharma industry is already aligned with...Trump’s vision,” she stated. The Indian pharmaceutical sector is likely to gain by Trump's policies, as per analysts.